Immune System Disorder and Cancer-Associated Cachexia
Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression....
Saved in:
| Published in | Cancers Vol. 16; no. 9; p. 1709 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
01.05.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers16091709 |
Cover
| Abstract | Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy. |
|---|---|
| AbstractList | Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy. Cancer-associated cachexia (CAC) is a serious condition wherein people with cancer lose muscle and fat, even with proper nutrition. It leads to weakness and can make treatment less effective. This review looks at how the body’s immune system and certain proteins affect CAC. Studies show that specific proteins, like IL-6 and TNF-α, play a crucial role in causing muscle and fat loss. Other cells in the immune system, called MDSCs, make CAC worse by causing inflammation. Clinical studies also found high levels of certain proteins in people with CAC. Understanding these processes might improve treatments, especially for those undergoing immunotherapy. A new drug called R-ketorolac has shown promise in reversing weight loss in animals. Combining drugs like this with immunotherapy could help patients with cancer suffering from CAC. However, more research is needed to fully understand how immune problems and CAC interact during treatment. Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy. Cancer-associated cachexia (CAC) is a serious condition wherein people with cancer lose muscle and fat, even with proper nutrition. It leads to weakness and can make treatment less effective. This review looks at how the body’s immune system and certain proteins affect CAC. Studies show that specific proteins, like IL-6 and TNF-α, play a crucial role in causing muscle and fat loss. Other cells in the immune system, called MDSCs, make CAC worse by causing inflammation. Clinical studies also found high levels of certain proteins in people with CAC. Understanding these processes might improve treatments, especially for those undergoing immunotherapy. A new drug called R-ketorolac has shown promise in reversing weight loss in animals. Combining drugs like this with immunotherapy could help patients with cancer suffering from CAC. However, more research is needed to fully understand how immune problems and CAC interact during treatment. Simple SummaryCancer-associated cachexia (CAC) is a serious condition wherein people with cancer lose muscle and fat, even with proper nutrition. It leads to weakness and can make treatment less effective. This review looks at how the body’s immune system and certain proteins affect CAC. Studies show that specific proteins, like IL-6 and TNF-α, play a crucial role in causing muscle and fat loss. Other cells in the immune system, called MDSCs, make CAC worse by causing inflammation. Clinical studies also found high levels of certain proteins in people with CAC. Understanding these processes might improve treatments, especially for those undergoing immunotherapy. A new drug called R-ketorolac has shown promise in reversing weight loss in animals. Combining drugs like this with immunotherapy could help patients with cancer suffering from CAC. However, more research is needed to fully understand how immune problems and CAC interact during treatment.AbstractCancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy. Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy.Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy. |
| Audience | Academic |
| Author | Zhang, Lingbing Bonomi, Philip D. |
| Author_xml | – sequence: 1 givenname: Lingbing surname: Zhang fullname: Zhang, Lingbing – sequence: 2 givenname: Philip D. surname: Bonomi fullname: Bonomi, Philip D. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38730660$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1PAyEQxYmpsbX27M008eJlLSwFdo9N_UxMPKjnDQuzSrMLFXYT-99La_1qlDlAJr_3mMw7RD3rLCB0TPA5pTmeKGkV-EA4zonA-R4apFikCef5tPfj3UejEBY4HkqJ4OIA9WkmKOYcDxC7bZrOwvhhFVpoxhcmOK_Bj6XV4_nGP5mF4JSRLaw76gXejDxC-5WsA4y29xA9XV0-zm-Su_vr2_nsLlFTSttEVYRCWVZlKkspica4KoFnTKscg2AsUyITpJwSwKCELBmb6gqEZlwzpXhGh-jsw3fp3WsHoS0aExTUtbTgulBQzGguMoZJRE930IXrvI3TbSiS0pzxb-pZ1lAYW7nWS7U2LWYip4wLQlikzv-gYmlojIohVCb2fwlOtp93ZQO6WHrTSL8qPvccgckHoLwLwUP1hRBcrMMsdsKMCrajUKaVrXE2zmLqf3Xvx3-hzw |
| CitedBy_id | crossref_primary_10_3322_caac_70000 crossref_primary_10_1016_j_cyto_2024_156821 crossref_primary_10_1016_j_tice_2025_102723 crossref_primary_10_1007_s12672_024_01309_1 crossref_primary_10_1007_s44337_024_00016_8 |
| Cites_doi | 10.3389/fimmu.2021.729182 10.3390/biomedicines10102497 10.4049/jimmunol.181.7.4676 10.1016/j.jamda.2010.02.012 10.1002/jcp.26811 10.1016/j.cyto.2016.02.015 10.1002/jcsm.12761 10.3390/cancers11111619 10.1089/jir.2018.0060 10.1002/jcsm.13422 10.1093/annonc/mdw016 10.1186/s12885-017-3178-8 10.1002/mco2.164 10.1002/jcsm.12441 10.1002/rco2.24 10.1016/j.cmet.2016.10.010 10.21037/tlcr-21-460 10.15252/emmm.201607052 10.1186/s12986-019-0409-9 10.1002/jcsm.12652 10.1517/14712598.2011.592826 10.3389/fcell.2022.960341 10.3892/mco.2022.2524 10.3390/jcm7120502 10.1517/14712598.2011.627850 10.4049/jimmunol.1302895 10.3389/fimmu.2022.793234 10.1016/j.jare.2023.04.018 10.7554/eLife.54095 10.3389/fonc.2020.00298 10.1001/jamaoncol.2017.4771 10.1038/nrdp.2017.105 10.1200/JCO.2005.04.2838 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.3390/cancers16091709 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Collection (ProQuest) Biological Sciences Research Library Biological Science Database (ProQuest) Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | A793567115 38730660 10_3390_cancers16091709 |
| Genre | Journal Article Review |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM PMFND 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c433t-cf13ebbfb2abaa1d00fbe685dc90e7558c7871b41e0ec7ab554dfe7d56d5cc683 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Fri Sep 05 14:20:36 EDT 2025 Sun Jul 13 05:07:30 EDT 2025 Tue Jun 17 22:10:18 EDT 2025 Tue Jun 10 21:07:33 EDT 2025 Thu Jan 02 22:24:27 EST 2025 Thu Apr 24 22:56:10 EDT 2025 Tue Jul 01 01:08:07 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | CAC TNF-α inflammation cytokines immune disorder IL-6 muscle wasting |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c433t-cf13ebbfb2abaa1d00fbe685dc90e7558c7871b41e0ec7ab554dfe7d56d5cc683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers16091709 |
| PMID | 38730660 |
| PQID | 3053123956 |
| PQPubID | 2032421 |
| ParticipantIDs | proquest_miscellaneous_3053978501 proquest_journals_3053123956 gale_infotracmisc_A793567115 gale_infotracacademiconefile_A793567115 pubmed_primary_38730660 crossref_primary_10_3390_cancers16091709 crossref_citationtrail_10_3390_cancers16091709 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-01 |
| PublicationDateYYYYMMDD | 2024-05-01 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2024 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | Marceca (ref_5) 2020; 10 Thibaut (ref_22) 2021; 12 Bayliss (ref_33) 2011; 11 Wang (ref_15) 2008; 181 Mezquita (ref_31) 2018; 4 ref_35 Arora (ref_16) 2020; 3 Ferrucci (ref_30) 2016; 27 Burfeind (ref_11) 2020; 9 Chasen (ref_34) 2011; 12 Cuenca (ref_21) 2014; 192 Wu (ref_1) 2023; 58 Khatami (ref_2) 2011; 11 Ma (ref_12) 2017; 9 Suleyman (ref_28) 2007; 59 Rounis (ref_18) 2021; 10 Han (ref_10) 2019; 16 Zhang (ref_24) 2021; 12 Baracos (ref_4) 2018; 4 Valencia (ref_9) 2019; 39 ref_25 Monk (ref_32) 2006; 24 Yamashita (ref_14) 2016; 89 Flint (ref_17) 2016; 24 Daas (ref_20) 2018; 234 Murari (ref_27) 2021; 12 ref_3 Fujii (ref_19) 2022; 16 ref_29 Sakowska (ref_8) 2022; 13 ref_26 Lima (ref_13) 2019; 10 Chrysostomou (ref_23) 2024; 15 Wang (ref_6) 2022; 3 ref_7 |
| References_xml | – volume: 12 start-page: 729182 year: 2021 ident: ref_27 article-title: Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.729182 – ident: ref_7 doi: 10.3390/biomedicines10102497 – volume: 181 start-page: 4676 year: 2008 ident: ref_15 article-title: A novel role for CD4+ T cells in the control of cachexia publication-title: J. Immunol. doi: 10.4049/jimmunol.181.7.4676 – volume: 12 start-page: 62 year: 2011 ident: ref_34 article-title: Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia publication-title: J. Am. Med. Dir. Assoc. doi: 10.1016/j.jamda.2010.02.012 – volume: 234 start-page: 13 year: 2018 ident: ref_20 article-title: Adipose tissue dysfunction in cancer cachexia publication-title: J. Cell. Physiol. doi: 10.1002/jcp.26811 – volume: 89 start-page: 122 year: 2016 ident: ref_14 article-title: White adipose tissue IFN-γ expression and signalling along the progression of rodent cancer cachexia publication-title: Cytokine doi: 10.1016/j.cyto.2016.02.015 – volume: 12 start-page: 1466 year: 2021 ident: ref_24 article-title: Association of systemic inflammation with survival in patients with cancer cachexia: Results from a multicentre cohort study publication-title: J. Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12761 – ident: ref_29 doi: 10.3390/cancers11111619 – volume: 39 start-page: 72 year: 2019 ident: ref_9 article-title: Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity publication-title: J. Interferon Cytokine Res. doi: 10.1089/jir.2018.0060 – volume: 15 start-page: 562 year: 2024 ident: ref_23 article-title: R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice publication-title: J. Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.13422 – volume: 27 start-page: 732 year: 2016 ident: ref_30 article-title: Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw016 – ident: ref_25 doi: 10.1186/s12885-017-3178-8 – volume: 3 start-page: e164 year: 2022 ident: ref_6 article-title: Targeting cancer cachexia: Molecular mechanisms and clinical study publication-title: MedComm doi: 10.1002/mco2.164 – volume: 10 start-page: 1045 year: 2019 ident: ref_13 article-title: Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia publication-title: J. Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12441 – volume: 3 start-page: 115 year: 2020 ident: ref_16 article-title: JAK Inhibitors Suppress Cancer Cachexia-Associated Anorexia and Adipose Wasting in Mice publication-title: JCSM Rapid Commun. doi: 10.1002/rco2.24 – ident: ref_35 – volume: 24 start-page: 672 year: 2016 ident: ref_17 article-title: Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity publication-title: Cell Metab. doi: 10.1016/j.cmet.2016.10.010 – volume: 10 start-page: 3538 year: 2021 ident: ref_18 article-title: Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: Results from a prospective, observational study publication-title: Transl. Lung Cancer Res. doi: 10.21037/tlcr-21-460 – volume: 9 start-page: 622 year: 2017 ident: ref_12 article-title: STAT3 promotes IFNγ/TNFα-induced muscle wasting in an NF-κB-dependent and IL-6-independent manner publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201607052 – volume: 16 start-page: 80 year: 2019 ident: ref_10 article-title: Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients publication-title: Nutr. Metab. doi: 10.1186/s12986-019-0409-9 – volume: 12 start-page: 70 year: 2021 ident: ref_22 article-title: Inflammation-induced cholestasis in cancer cachexia publication-title: J. Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12652 – volume: 59 start-page: 247 year: 2007 ident: ref_28 article-title: Anti-inflammatory and side effects of cyclo-oxygenase inhibitors publication-title: Pharmacol. Rep. – volume: 11 start-page: 1419 year: 2011 ident: ref_2 article-title: Unresolved inflammation:‘immune tsunami’or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer publication-title: Expert Opin. Biol. Ther. doi: 10.1517/14712598.2011.592826 – ident: ref_3 doi: 10.3389/fcell.2022.960341 – volume: 16 start-page: 91 year: 2022 ident: ref_19 article-title: Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer publication-title: Mol. Clin. Oncol. doi: 10.3892/mco.2022.2524 – ident: ref_26 doi: 10.3390/jcm7120502 – volume: 11 start-page: 1663 year: 2011 ident: ref_33 article-title: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer publication-title: Expert Opin. Biol. Ther. doi: 10.1517/14712598.2011.627850 – volume: 192 start-page: 6111 year: 2014 ident: ref_21 article-title: Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia publication-title: J. Immunol. doi: 10.4049/jimmunol.1302895 – volume: 13 start-page: 793234 year: 2022 ident: ref_8 article-title: Autoimmunity and Cancer—Two Sides of the Same Coin publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.793234 – volume: 58 start-page: 45 year: 2023 ident: ref_1 article-title: Immunoregulation in cancer-associated cachexia publication-title: J. Adv. Res. doi: 10.1016/j.jare.2023.04.018 – volume: 9 start-page: e54095 year: 2020 ident: ref_11 article-title: Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer publication-title: Elife doi: 10.7554/eLife.54095 – volume: 10 start-page: 298 year: 2020 ident: ref_5 article-title: Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00298 – volume: 4 start-page: 351 year: 2018 ident: ref_31 article-title: Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2017.4771 – volume: 4 start-page: 17105 year: 2018 ident: ref_4 article-title: Cancer-associated cachexia publication-title: Nat. Rev. Dis. Primers doi: 10.1038/nrdp.2017.105 – volume: 24 start-page: 1852 year: 2006 ident: ref_32 article-title: Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.04.2838 |
| SSID | ssj0000331767 |
| Score | 2.3762891 |
| SecondaryResourceType | review_article |
| Snippet | Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes... Cancer-associated cachexia (CAC) is a serious condition wherein people with cancer lose muscle and fat, even with proper nutrition. It leads to weakness and... Simple SummaryCancer-associated cachexia (CAC) is a serious condition wherein people with cancer lose muscle and fat, even with proper nutrition. It leads to... |
| SourceID | proquest gale pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 1709 |
| SubjectTerms | Adipocytes Adipose tissue Anorexia Body fat Cachexia Cancer Cancer therapies Cytokines Development and progression Drug therapy, Combination Health aspects Immune response Immune system Immunomodulation Immunosuppressive agents Immunotherapy Inflammation Interleukin 6 Interleukin 8 Ketorolac Leukocytes (neutrophilic) Lymphocytes Metabolism Morbidity Neutrophils NF-κB protein Oncology, Experimental Pancreatic cancer Patients Suppressor cells Tofacitinib Transforming growth factor-b Transforming growth factors Tumor necrosis factor Tumor necrosis factor-α Tumors γ-Interferon |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8NAEB60gvgi3karRBD0JbrJZnfbBxEVpQotIgq-hb0CgqS1B_jznWmSqgV9zR4MMzsz32bnADjmaA5Txm3klFbUwsxFmlN_E-9NyqUVeUrJyd2e7LykD6_idQF6dS4MhVXWNnFqqF3f0j_yc06nJeEI5y8HHxF1jaLX1bqFhq5aK7iLaYmxRVhCGgRrwNL1be_xafbXhXH0l1KVNX443vfPLTF3OIolOk5FYYk_3NO8kZ6DnlMXdLcGqxV2DK9KYa_Dgi82YLlbvY5vgrinZA8fllXIw7qwZqgLF95MCYhqaXj6gvL6fNNb8HJ3-3zTiaq2CJFNOR9HNo-5NyY3iTZax46x3HjZEs62mVdCtCwqYWzS2DNvlTYIGFzulRPSCWtli29Do-gXfhdC49vorXyc5ApxkeaIHZKcW9w8b6fSugDOam5ktqoZTq0r3jO8OxD7sjn2BXA6WzAoy2X8PfWE2JuRIuGeVlf5AEgZlaTKrtByCKkQsQbQ_DUTFcD-Hq4FlFUKOMq-j0sAR7NhWklBZYXvT8o5eIkWLA5gpxTsjGjeQtMnJdv7f_N9WEkQ5ZQRkE1ojIcTf4AoZWwOq6P3BRWk5n0 priority: 102 providerName: ProQuest |
| Title | Immune System Disorder and Cancer-Associated Cachexia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38730660 https://www.proquest.com/docview/3053123956 https://www.proquest.com/docview/3053978501 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZSwMxEB48QHwRb9ejrCDoy-ruZpO0DyIqnmARsdC3JdeCULbaVtB_78welZbqa5IZwkwy8w3JzAAcMTSHSchMYKWS1MLMBopRfxPndMKE4VlCyclPbXHfSR67vPvbDqgS4HBmaEf9pDqD3unXx_cFXvhzijgxZD8zJJ_BMBLo-yQl8y0Wj0X0j6_C-oVZZugqhSzL-8yim_BM0_Z5CnUW3ud2FVYq2OhflnpegzmXr8PSU_UwvgH8gfI8nF8WIPfrmpq-yq1_XWwgqBXhaARV9fWmNqFze_N6fR9UHRECkzA2CkwWMad1pmOllYpsGGbaiSa3phU6yXnT4P2LdBK50BmpNGIFmzlpubDcGNFkW7CQ93O3A752LXRULooziZBIMYQNccYMMs9aiTDWg9NaGqmpyoVT14peimEDiS-dEp8HJ2OC97JSxt9Lj0m8KWkVeRpVpQLgzqgaVXqJRoMLiWDVg_2JlXj2zeR0raC0PjopI7sSMwz8PDgcTxMl_SfLXf-zXIPxMw8jD7ZLxY43zZpo9YQId_9nvgfLMQKc8vPjPiyMBp_uAAHKSDdg8eqm_fzSgPm7btQojuEPXtvmWw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEN8EBgQJBC9hThzb7cOExtjUsrVCaJP2lvnjIk2a0rF2Av45_jbuGqewSvC218Q-WXfnu5_t-wB4LckclkL6LBhruIVZyKzk_iaIrpTaq7rk5OTxRA-Pys_H6ngNfnW5MBxW2dnEhaEOU8935JuStaWQBOc_nH_LuGsUv652LTRsbK0QthYlxmJixz7-_E5HuNnW6BPJ-01R7O0e7gyz2GUg86WU88zXuUTnaldYZ20ehKgd6r4KfiDQKNX3pNO5K3MU6I115H9DjSYoHZT3ui-J7g1YL_kCpQfrH3cnX74ub3mEJP-sTVtTSMqB2PQszItZrslRGw6D_MsdrjqFFai7cHl7d-FOxKrpdqtc92ANm_twcxxf4x-AGnFyCaZt1fO0K-SZ2iakO4sFZJ30kb-Qfvw4tQ_h6FoY9Ah6zbTBJ5A6HJB3xLyoDeEwKwmrFLX0RLwelNqHBN533Kh8rFHOrTLOKjqrMPuqFfYl8G454bwtz_HvoW-ZvRVvXKLpbcw_oJVxCaxqmyyV0oYQcgIbV0bShvNXf3cCquKGn1V_1DOBV8vfPJOD2BqcXrZj6NCuRJ7A41awy0XLPplarcXT_xN_CbeGh-OD6mA02X8GtwtCWG305Qb05heX-JwQ0ty9iGqYwsl1a_5vY_gmLQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1dTxNBcIKQEF8MCuoJ6JFo8OXs3u3tbvtADAINFWmIkYS3Yz8TE3NFWqL8RX4VM729Kk3gjdfb3clmvud2PgDec1SHJeM2c0orGmHmMs1pvon3puTSilBScfLxUB6ell_PxNkC3LS1MJRW2erEqaJ2I0v_yDucuKXg6M53QkyLONnvf774ndEEKXppbcdp6Dhmwe1M243FIo8jf_0Hw7nxzmAfaf-hKPoHP_YOszhxILMl55PMhpx7Y4IptNE6d4wF42VXONtjXgnRtcjfuSlzz7xV2qAtdsErJ6QT1souR7hPYEmh1cdAcOnLwfDk--yPD-Noq6Vq-gtx3mMdS4S9HOcSjbailMj_TOO8gZhze6fmr78Cz6Lfmu42jPYcFnz9ApaP48v8KogBFZr4tOmAnrZNPVNdu3RveoGs5QRPX5BX_v7Ua3D6KAh6CYv1qPavITW-h5bS50VQ6JNpjn5LEbhF4KFXSusS-NRio7KxXzmNzfhVYdxC6Kvm0JfAx9mBi6ZVx_1btwm9FQkxwrQ61iLgzagdVrWLWktIhd5yAht3dqLw2bvLLYGqKPzj6h-rJrA1W6aTlNBW-9FVswcDeMHyBF41hJ1dmndR7UrJ3jwM_B0sowRU3wbDo3V4WqCz1SRibsDi5PLKb6KzNDFvIxemcP7YjH8L-NEqcQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immune+System+Disorder+and+Cancer-Associated+Cachexia&rft.jtitle=Cancers&rft.au=Zhang%2C+Lingbing&rft.au=Bonomi%2C+Philip+D&rft.date=2024-05-01&rft.pub=MDPI+AG&rft.eissn=2072-6694&rft.volume=16&rft.issue=9&rft.spage=1709&rft_id=info:doi/10.3390%2Fcancers16091709&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |